Development of a novel imaging modality for adoptive cell therapy

摘要： 最近，一种新的癌症治疗方法被称为过继细胞疗法，显示出很高的前景。这 治疗方法包括用T细胞或自然杀伤(NK)细胞等免疫细胞治疗患者，而不是 药物治疗。虽然一些细胞疗法已经显示出对至少一部分癌症的高度希望，但主要的 这一领域发展中的技术挑战是缺乏对这些细胞所在位置的了解 一旦它们被注入体内。虽然很容易监测血液中是否有输注者 对于免疫细胞，目前还没有令人满意的方法来监控进入组织的细胞(例如，结肠肿瘤)。在……里面 在这项提议中，我们将开发一种使用纳米气泡(NBS)标记免疫细胞的新方法。这些标签上标着 然后，可以使用超声波对细胞进行非侵入性监测。因为国家安全局是已经是FDA的一个组成部分 批准的产品，我们预计这种方法不仅是安全的，而且可以快速翻译成人类 测试。希望这项工作将产生新的技术，使我们能够监测贩运 免疫细胞疗法，以便我们可以最佳地选择哪些患者/肿瘤类型将从 给出了细胞治疗产品。

Abstract: Recently a new therapeutic approach for cancer has exhibited high promise termed adoptive cell therapy. This approach involves treating patients with immune cells such as T cells or Natural Killer (NK) cells instead of drug therapy. While some cell therapies have exhibited high promise for at least a subset of cancers, a major technological challenge in the development of this field is the lack of knowledge of where these cells reside in the body once they are infused. While it is readily easy to monitor the blood for the presence of the infused immune cells, there is no satisfactory method to monitor the cells that traffic into tissue (ex. colon tumors). In this proposal, we will develop a novel method to label immune cells using nanobubbles (NBs). These labelled cells then can be monitored non-invasively using an ultrasound. As NBs are a component of an already FDA approved product, we anticipate this approach will not only be safe but can be translated quickly to human testing. It is hoped that this work will lead to new technology that will enable us to monitor the trafficking of immune cell therapies so that we can optimally select which patients/tumor types would most benefit from a given cell therapy product.